Figure 5.

Long‐term achievement of absolute PASI thresholds (mNRI and LOCF). Percentage of patients achieving absolute PASI scores of (a) ≤3, (b) ≤1, (c) or = 0 over long‐term, continuous risankizumab treatment (OC, LOCF, and mNRI). *The drop‐off in response rates (mNRI) is attributed to the lower number of observations at this timepoint, as many patients had not yet completed 172 weeks of treatment by the time of this analysis. Due to more missing data at this time point, the mixed‐effect analysis results in lower response rates. Imputed patients who discontinued due to worsening of symptoms as non‐responders; all other missing data handled using mixed‐effects models. LOCF, last observation carried forward; mNRI, modified non‐responder Imputation; OC, observed cases; PASI, Psoriasis Area and Severity Index.